[A25-142] Nivolumab (oesophageal or gastro-oesophageal junction cancer, adjuvant) – Addendum to Project A25-88
Last updated 18.12.2025
Project no.:
A25-142
Commission:
Commission awarded on 12.11.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy
Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
https://doi.org/10.60584/A25-142_en
| Project no. | Title | Status |
|---|---|---|
| A25-88 | Nivolumab (oesophageal or gastro-oesophageal junction cancer, adjuvant) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-154 | Nivolumab (urothelial carcinoma, adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
Federal Joint Committee (G-BA)
2025-12-18 A G-BA decision was published.